Hampig Raphaël Kourié

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Antoine Mouawad · 1 shared paper, 2024 · strength 0.28
   • Paper How to find a needle in a haystack: a systematic review on targeting KRAS wild-type pancreatic cancer. DOI 10.1080/14796694.2024.2355078↗
2. Marwan G. Ghosn · 3 shared papers, 2016 · strength 0.22
   • Paper Is metastatic pancreatic cancer an untargetable malignancy? DOI 10.4251/wjgo.v8.i3.297↗
   • Paper Road map for pain management in pancreatic cancer: A review. DOI 10.4251/wjgo.v8.i8.599↗
   • Paper Dilemma of first line regimens in metastatic pancreatic adenocarcinoma. DOI 10.3748/wjg.v22.i46.10124↗
3. Joseph Gergi Kattan · 2 shared papers, 2016–2017 · strength 0.19
   • Paper Will gemcitabine monotherapy be dethroned as the adjuvant chemotherapy in pancreatic adenocarcinoma? DOI 10.2217/fon-2016-0316↗
   • Paper Dilemma of first line regimens in metastatic pancreatic adenocarcinoma. DOI 10.3748/wjg.v22.i46.10124↗
4. Imad Radi · 1 shared paper, 2021 · strength 0.17
   • Paper Perioperative chemotherapy with modified FOLFIRINOX for nonmetastatic pancreatic cancer: a new standard of care? DOI 10.2217/fon-2020-0836↗
5. Samer Tabch · 1 shared paper, 2016 · strength 0.10
   • Paper EARLY INCREASE of CA 19-9 in ADVANCED PANCREATIC CANCER RECEIVING FOLFIRINOX. Is it a sign of efficacy?. DOI 10.12816/0027466↗
6. Fadi Farhat · 1 shared paper, 2016 · strength 0.10
   • Paper EARLY INCREASE of CA 19-9 in ADVANCED PANCREATIC CANCER RECEIVING FOLFIRINOX. Is it a sign of efficacy?. DOI 10.12816/0027466↗
7. Édouard Auclin · 1 shared paper, 2019 · strength 0.08
   • Paper Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline an… DOI 10.1016/j.clinre.2019.03.007↗
8. Daniel Pietrasz · 1 shared paper, 2019 · strength 0.08
   • Paper Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline an… DOI 10.1016/j.clinre.2019.03.007↗
9. Sébastien Gaujoux · 1 shared paper, 2019 · strength 0.08
   • Paper Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline an… DOI 10.1016/j.clinre.2019.03.007↗
10. Alain Sauvanet · 1 shared paper, 2019 · strength 0.08
    • Paper Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline an… DOI 10.1016/j.clinre.2019.03.007↗
11. António Sá Cunha · 1 shared paper, 2019 · strength 0.08
    • Paper Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline an… DOI 10.1016/j.clinre.2019.03.007↗
12. Isabelle Trouilloud · 1 shared paper, 2019 · strength 0.08
    • Paper Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline an… DOI 10.1016/j.clinre.2019.03.007↗
13. Julien Taı̈eb · 1 shared paper, 2019 · strength 0.08
    • Paper Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline an… DOI 10.1016/j.clinre.2019.03.007↗
14. Jean‐Baptiste Bachet · 1 shared paper, 2019 · strength 0.08
    • Paper Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline an… DOI 10.1016/j.clinre.2019.03.007↗
15. Marie José Lahoud · 1 shared paper, 2016 · strength 0.08
    • Paper Road map for pain management in pancreatic cancer: A review. DOI 10.4251/wjgo.v8.i8.599↗
16. Tarek Assi · 1 shared paper, 2016 · strength 0.07
    • Paper Dilemma of first line regimens in metastatic pancreatic adenocarcinoma. DOI 10.3748/wjg.v22.i46.10124↗
17. Elie Rassy · 1 shared paper, 2016 · strength 0.07
    • Paper Dilemma of first line regimens in metastatic pancreatic adenocarcinoma. DOI 10.3748/wjg.v22.i46.10124↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.